Loading True North Map…
Capability profile
Bioprinted human adrenocortical-cell tissues under development for primary adrenal insufficiency, supported by supplier-authored animal research.
Bioprinted human adrenocortical-cell tissues under development for primary adrenal insufficiency, supported by supplier-authored animal research.
These describe the reviewed application scope, not confirmed deployments, released requirements or procurement eligibility.
Supplier lists Preclinical stage. ENDO2025 supplier-authored abstract and conference-owner context establish animal research presentation, not independent replication, clinical cure or an approved treatment.
Research/programme partnering route; require the intended cell/material/implant configuration and next clinical/regulatory/manufacturing milestones.
A technology readiness level is not established by the reviewed public sources.
No reviewed Mission area or released Defence need connection is currently published.
These records support this capability and its published Mission area and Defence need connections. A source count is not a count of independent confirmations.
Endocrine Society
Source type: official report
Supports: Capability · maturity
Conference owner reports Aspect researcher preclinical adrenal BTT presentation for primary adrenal insufficiency. This is corroboration of conference/research context, not independent replication of supplier-authored experimental results.
Source type: official company product
Supports: Capability · core features
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · technical tags
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · display lead
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · commercial availability
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · catalogue teaser
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
ClinicalTrials.gov / National Library of Medicine
Source type: official report
Supports: Capability · core features
October4 2026 exactAspectBiosystemsClinicalTrials.gov andHealthCanada keywordsearchallstatuses/provinces/nodaterestrictions returnednorecords/results. Boundednegative doesnotproveglobalabsence,otheralias/sponsorabsence,regulatoryrejection ordiabetesphase; onlypreclinicalAdrenal stageaffirmed.
Aspect Biosystems research authors
Source type: official report
Supports: Capability · maturity
Aspect-authored ENDO2025 original reports engineered bioprinted adrenal tissues and animal research. Presentation July14 2025 is distinct from October22 2025 journal publication; neither establishes human clinical cure, treatment authorization or defence application.
Supports: Capability · summary
Aspect-authored ENDO2025 original reports engineered bioprinted adrenal tissues and animal research. Presentation July14 2025 is distinct from October22 2025 journal publication; neither establishes human clinical cure, treatment authorization or defence application.
Capability · core features
Aspect Biosystems
Source type: official company product
Supports: Capability · commercial availability
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Public sources cited · Facts and assessments kept separate · Human review
Loading related records…
Supports: Capability · name
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · defence applications
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · core features
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · maturity
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · technology readiness level
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · slug
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · summary
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · core features
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · technical tags
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · technical tags
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · capability type
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Capability · technicaldomainslugs
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
OriginalauthorPDFp1paras3–5:primaryhumanadrenocorticalcells/supportingbiomaterial/immuneprotectiveshell,invitroACTH-responsivecortisol,implantsinadrenalectomizedmice withcortisol/ACTH/survivalresponse andfunctionretrieved-cellresponse throughsixmonths. Human-to-mousestudy isxenogeneic,intendedhumanproductallogeneic; noabstractdose,n,effectsizes orformula supplied.
Supports: Capability · catalogue teaser
Aspect-authored ENDO2025 original reports engineered bioprinted adrenal tissues and animal research. Presentation July14 2025 is distinct from October22 2025 journal publication; neither establishes human clinical cure, treatment authorization or defence application.
Supports: Capability · display lead
Aspect-authored ENDO2025 original reports engineered bioprinted adrenal tissues and animal research. Presentation July14 2025 is distinct from October22 2025 journal publication; neither establishes human clinical cure, treatment authorization or defence application.
